| アブストラクト | INTRODUCTION: Over the last few years, improved outcomes in patients with chronic lymphocytic leukemia (CLL) have been credited to the introduction of novel agents for its treatment. However, the overall cardiovascular safety profile of these agents has not been studied adequately. METHODS: We searched the Food and Drug Administration Adverse Event Reporting System (FAERS) database for adverse events reported for several of these novel agents: ibrutinib, acalabrutinib, venetoclax, and idelalisib. RESULTS: A total of 6074 cardiac adverse events were identified; ibrutinib (4832/36581; 13.2%) was found to have the highest risk of cardiac adverse events. The frequency of atrial fibrillation was highest (41.5%) in the ibrutinib group, while the idelalisib and acalabrutinib groups had the highest reported frequencies of heart failure (25.1%) and myocardial infarction (13.6%), respectively. Hypertension was noted to be relatively higher in the acalabrutinib (25.6%) and venetoclax (11.8%) groups. Overall reported mortality associated with cardiac events was highest in the venetoclax (29.4%) and idelalisib (27.1%) groups. CONCLUSION: Novel agents in the CLL armamentarium have been associated with several cardiovascular adverse events. Further studies are needed to identify high-risk groups that would benefit from robust cardiovascular surveillance after initiation of treatment with these novel agents. |
|---|
| ジャーナル名 | International journal of cardiology |
|---|
| 投稿日 | 2021/10/16 |
|---|
| 投稿者 | Grewal, Udhayvir Singh; Thotamgari, Sahith Reddy; Sheth, Aakash Rajendra; Gaddam, Shiva Jashwanth; Ahmad, Javaria; Beedupalli, Kavitha; Dominic, Paari |
|---|
| 組織名 | Department of Internal Medicine, Louisiana State University Health Sciences;Center, Shreveport, LA, USA.;Division of Hematology and Oncology, Department of Medicine, Louisiana State;University Health Sciences Center, Shreveport, LA, USA.;Division of Cardiology, Department of Medicine, and Center for Cardiovascular;Diseases and Sciences, Louisiana State University Health Sciences Center,;Shreveport, LA, USA. Electronic address: paari.dominic@lsuhs.edu. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/34653574/ |
|---|
